A Phase 2 Open-label Multicenter Randomized Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)

Brief description of study

The main purpose of this study is to determine the effectiveness of durvalumab in combination with other experimental drugs to the effectiveness of durvalumab when used alone by assessing tumor changes following therapy in the resected NSCLC lesions after resection. The study is also being done to evaluate the safety and tolerability of durvalumab when used alone and in combination with other experimental drugs in people with non-small cell lung cancer. The study will also evaluate how much of the study drug(s) is in your blood at various times, whether your immune system becomes activated to help control the cancer following treatment with the study drug(s) and whether your body produces antibodies against any of the study drugs as a response to the treatment. Further, this study will evaluate changes in microbiome (microorganisms in specific environment, in this case our body or part of the body) that are compared to clinical outcome of the durvalumab when used alone or in combination with other experimental drugs.

Clinical Study Identifier: s18-01676
ClinicalTrials.gov Identifier: NCT03794544
Principal Investigator: Vamsidhar Velcheti
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.